SVCM
OVID icon

Saturn V Capital Management’s Ovid Therapeutics OVID Stock Holding History

Saturn V Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Sell
663,060
-3,503,606
-84% -$9.04M 0.26% 23
2026
Q1 		$9.25M Buy
4,166,666
+1,666,666
+67% +$2.98M 1.68% 17
2025
Q4 		$4.08M Buy
+2,500,000
New +$3.85M 0.75% 19

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Saturn V Capital Management's OVID Position: Q2 2026 in Review

Saturn V Capital Management reduced its Ovid Therapeutics (OVID) stake by 84% in Q2 2026, selling an estimated $9.04M and leaving 663,060 shares worth $1.78M. The position accounts for 0.26% of the portfolio, ranked #23.

Saturn V Capital Management first reported a position in OVID in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.25M in Q1 2026. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Saturn V Capital Management held 663,060 shares of Ovid Therapeutics worth $1.78M as of Q2 2026.
  • Saturn V Capital Management sold 3,503,606 Ovid Therapeutics shares in Q2 2026, an estimated $9.04M.
  • Ovid Therapeutics made up 0.26% of Saturn V Capital Management's portfolio in Q2 2026, its #23 holding.
  • Saturn V Capital Management first reported a position in Ovid Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Saturn V Capital Management's Ovid Therapeutics position peaked at $9.25M in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.